Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3218)	4/24/2015 1:32:24 PM
From: Jibacoa	Respond to of 3722

COCP is up 14% on a volume of 1.2Ms, still a little below its ADV.<g> The stock is up for 3rd day on a roll after founding support at its EMA50 and the $1 level.<g> The stock has a good performance since the up-move that started on Fe9 from the $0,47 level.<g> The Insiders including Dr,P.Frost and R.Schinazi, have been persistent buyers. finance.yahoo.com I am also long COCP.<g> Bernard

To: Jibacoa who wrote (3218)	4/24/2015 4:41:52 PM
From: mopgcw	Respond to of 3722

Thanks Bernard. I am very long RIGL as well, having avg'd down here and there. strong close on no news that I saw. very interesting to see if something comes of it. best, geo

To: Jibacoa who wrote (3218)	4/24/2015 6:36:23 PM
From: Biotech Jim	Read Replies (2) \| Respond to of 3722

I told my brother this morning that we should be taking RIGL profits in the $6-8 range. I bought heavily in Jan, and also held significant shares from 1-2 years back. I also bought mucho shares in my Mother's account, now distributed to all her children. The ITP studies in Ph 3 should be positive, and read out in Q1 2016. Still trying to figure out the reason for the bump after hours yesterday and continuing today. Some fund initiating a position? Or delayed reaction to the BMY collaboration? Here is a quote from that BMS/RIGL PR: "This collaboration places our TGF beta receptor kinase inhibitor program into the hands of Bristol-Myers Squibb, a premier immuno-oncology company. Together, we believe TGF beta inhibition may offer novel therapeutic opportunities in oncology treatments" http://news.bms.com/press-release/rd-news/rigel-and-bristol-myers-squibb-announce-research-and-development-collaboration